Eris delivers 11% yoy growth in Domestic Formulations with 37% EBIDTA margin in FY26

Eris Lifesciences Limited ("Eris Lifesciences" or the "Company") (BSE: 540596; NSE: ERIS), a leading Indian branded formulations manufacturing company, today announced its earnings for the quarter and full year ended March 31, 2026.

Q4 and FY2026 Key Financial Highlights:

- DBF business revenue growth of 12% YoY in Q4 and 11% YoY in FY26 - EBIDTA margin 37%
- Consolidated Revenue growth 7% YoY in Q4 and 8% YoY in FY26 - EBIDTA margin 36%
- Consolidated Q4 PAT Rs. 279 Cr with a 174% growth, FY26 PAT Rs. 648 Cr, with a 73% growth
- Net debt as of March 31, 2026, stood at Rs. 2,255 Cr

Commenting on the results, Mr. Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd, said, "Our Domestic Formulations business delivered a 11% revenue growth in FY26 with a 12% EBIDTA growth and industry leading EBIDTA margin of 37%. Our Insulins franchise has outpaced market growth by 5x in FY26 with a market share expansion from 12% to 16%. Our GLP brand Sundae has gotten off to a strong start, which reflects the present standing of the company in the Injectable Diabesity space. Sundae ranks #1 by volume (among injectables) in its very first month of launch, which validates our thesis of being able to leverage our Insulins platform to secure a strong position in the GLP segment."

Shares of Eris Lifesciences Limited was last trading in BSE at Rs. 1459.50 as compared to the previous close of Rs. 1337.35. The total number of shares traded during the day was 56499 in over 3511 trades.

The stock hit an intraday high of Rs. 1493.95 and intraday low of 1332.20. The net turnover during the day was Rs. 81459791.00.

Source : Equity Bulls

Keywords

ErisLifesciences INE406M01024 Pharmaceuticals Q4FY26 Q4FY2026 FY26 FY2026 ResultUpdate